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Abstract
Background: Initial combination therapy with ambrisentan and tadalafil reduced the risk of clinical failure events
for treatment-naïve participants with pulmonary arterial hypertension (PAH) as compared to monotherapy. Previous
studies in PAH have demonstrated greater treatment benefits in more symptomatic participants.
Methods: AMBITION was an event-driven, double-blind study in which participants were randomized 2:1:1 to once-
daily initial combination therapy with ambrisentan 10 mg plus tadalafil 40 mg, ambrisentan 10 mg plus placebo, or
tadalafil 40 mg plus placebo. In this pre-specified subgroup analysis, we compared the efficacy data between those
with functional class (FC) II vs. FC III symptoms at baseline.
Results: This analysis included 500 participants in the previously defined primary analysis set (n = 155 FC II, n = 345
FC III). Comparing combination therapy to pooled monotherapy, the risk of clinical failure events was reduced by
79% (hazard ratio, 0.21 [95% confidence interval: 0.071, 0.63]) for FC II patients and 42% (hazard ratio, 0.58 [95%
confidence interval: 0.39, 0.86]) for FC III patients. In a post-hoc analysis, the risk of first hospitalization for worsening
PAH was also reduced by combination therapy, particularly for FC II patients (0 combination vs. 11 [14%] pooled
monotherapy). Adverse events were frequent but comparable between the subgroups.
Conclusions: Treatment benefit from initial combination therapy appeared at least as great for FC II as for FC III
participants. Hospitalizations for worsening PAH were not observed in FC II participants assigned to combination.
The present data support an initial combination strategy for newly diagnosed patients even when symptoms are
less severe.
Funded by Gilead Sciences, Inc. and GlaxoSmithKline; AMBITION ClinicalTrials.gov number, NCT01178073.
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Background
Pulmonary arterial hypertension (PAH) is a progressive
disease of the pulmonary vasculature characterized by
vasoconstriction, vascular inflammation and fibrosis, and
in situ thrombosis [1]. The etiology is poorly under-
stood, and many patients progress to right ventricular
failure and death despite current therapy [2]. Parenteral
prostacyclin analogues are uniformly recommended to
treat patients with high-risk manifestations, but the opti-
mal use of oral therapies in low- or intermediate-risk pa-
tients remains an important area of research [3].
Sequential combination therapy delayed clinical worsen-
ing in the registration trials for macitentan [4], riociguat
[5], and selexipag [6]. In each of these studies, partici-
pants with FC III symptoms drove the primary treat-
ment effect.
The AMBITION study demonstrated a 50% reduction
in the risk of clinical failure for treatment naïve PAH par-
ticipants who began initial combination therapy (ambri-
sentan and tadalafil) as compared to those assigned
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: Jim_White@urmc.rochester.edu
1Division of Pulmonary & Critical Care Medicine, University of Rochester
Medical Center, 400 Red Creek Dr, Rochester, NY 14623, USA
Full list of author information is available at the end of the article
White et al. Respiratory Research          (2019) 20:208 
https://doi.org/10.1186/s12931-019-1180-1
monotherapy [7]. The benefit of initial combination ther-
apy was primarily attributable to a reduction in PAH-re-
lated hospitalizations. The present paper describes a
prespecified subgroup analysis which planned to evaluate
the primary outcome in participants with FC II symptoms
as compared to those with more advanced FC III symp-
toms. Based on previous studies, we hypothesized that the
statistically and clinically relevant benefits of initial com-
bination therapy would be largely attributable to those
with FC III symptoms at baseline.
Methods
Participants and treatments
Details of the study have been reported previously [7]. Each
enrolling site had institutional review before consenting
participants, and each participant provided written in-
formed consent before study procedures. Briefly, partici-
pants were treatment-naïve and symptomatic patients with
idiopathic or heritable PAH; or PAH associated with con-
nective tissue disease, drugs or toxins, stable HIV infection,
or congenital heart defects repaired > 1 year prior to screen-
ing. Following initial enrollment of ~ 150 patients, a blinded
review of demographic data revealed a greater than antici-
pated prevalence of risk factors for left ventricular diastolic
dysfunction. Protocol amendment 2 therefore restricted en-
rollment to participants with no more than 2 risk factors
for left ventricular diastolic dysfunction. This amendment
also specified a more rigorous hemodynamic definition for
participants with pulmonary capillary wedge pressures be-
tween 13 and 15mmHg. Participants meeting amendment
2 criteria have been referred to as the primary analysis set
(PAS, n = 500), and they are the focus of this analysis.
This event-driven study required 105 events in the
PAS for ~ 97% power to detect a 53% reduction in haz-
ard rate between combination therapy and pooled
monotherapy. The primary endpoint was time to first
clinical failure event (TtCF). The components of TtCF
are provided in Table 1; a blinded, independent commit-
tee adjudicated all components (and all hospitalizations
through the end of study.)
Randomization was 2:1:1 to combination therapy or
monotherapy (ambrisentan or tadalafil monotherapy),
stratified by underlying etiology of PAH and baseline
FC. The study was conducted in accordance with the
Declaration of Helsinki and its amendments (Clinical-
Trials.gov number, NCT01178073). The protocol was
approved by the institutional review board at each enrol-
ling center (Additional file 1).
Statistical analysis
Analyses are presented by baseline FC and include prespe-
cified analyses on TtCF, 6-min walk distance, and satisfac-
tory clinical response (other analyses were post-hoc
following the initial observations). The Kaplan-Meier
product limit method was used to generate survival curves
for TtCF and time to first hospitalization for worsening
PAH; treatment groups were compared using the stratified
log-rank test. Cox proportional-hazards regression models
were used to calculate the hazard ratios and 95% confi-
dence intervals. As typical for similar analyses, the alpha
level for the interaction between primary outcome and
subgroup was set a priori at 0.1. Detailed statistical




Patient disposition is shown in Fig. 1. FC II participants
were equally distributed in each treatment group
(Table 2) by design. Participants with FC III symptoms
tended to be older, and there were more participants
with CTD-associated PAH in FC III as compared to FC
II (in all treatment groups). More males with FC II
symptoms were randomized to combination therapy;
otherwise treatment assignments were balanced. Baseline
6MWD and NT-proBNP levels were similar among the
FC II treatment groups and noticeably different from the
FC III participants, consistent with the investigator
assigned FC (Fig. 2). Importantly, despite having mild
functional limitations, median 6MWD and NT-proBNP
Table 1 Components and Definitions of the Primary Endpoint
Component Definition
Death (all-cause) Certificate of death
Hospitalization for worsening
PAH
Adjudicated and defined as any hospitalization for worsening PAH, lung or heart/lung transplant, atrial septostomy;
participants who initiated parenteral prostanoid therapy were included in this group
Disease progression Adjudicated and defined as a (decrease of > 15% from baseline in 6MWD combined with WHO FC III or IV
symptoms) at 2 consecutive visits separated by ≥14 days
Unsatisfactory long-term clinical
response
Adjudicated and requiring participation in the study for ≥6 months; defined as sustained WHO FC III symptoms
AND any decrease from baseline in 6MWD at 2 consecutive visits separated by ≥14 days
From New England Journal of Medicine. Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, Peacock AJ, Simonneau G, Vachiery JL, Grünig E,
Oudiz RJ, Vonk-Noordegraaf A, White RJ, Blair C, Gillies H, Miller KL, Harris JH, Langley J, Rubin LJ; AMBITION Investigators. Initial use of ambrisentan plus tadalafil
in pulmonary arterial hypertension. Volume 373, Pages 834–844. Copyright© (2015) Massachusetts Medical Society. Reprinted with permission from Massachusetts
Medical Society
6MWD 6-min walk distance, FC Functional class, PAH Pulmonary arterial hypertension, WHO World Health Organization
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in the FC II group suggested that many participants
would be at ‘intermediate risk’ for mortality according to
ESC/ERS guidelines [3]. Table 2 also illustrates that pul-
monary vascular resistance tended to be higher in those
assessed as FC III although the differences were not as
prominent as for 6MWD and NT-proBNP.
Primary endpoint
The Kaplan-Meier representation of TtCF comparing
combination therapy vs. pooled monotherapy for the
subgroups with FC II or III symptoms at baseline is
shown in Fig. 3a and b respectively. Figure 3a illustrates
the few events in the combination therapy group. The
Forest plot of TtCF (Fig. 4) demonstrates that, compared
to the results from pooled monotherapy, there is a 50%
risk reduction in events for the entire PAS. While partic-
ipants assigned to initial combination therapy had lower
aggregate risk compared to monotherapy, a significantly
greater reduction in the risk of clinical events was ob-
served for the FC II cohort (hazard ratio 0.21 [95% CI:
0.07, 0.63]) as compared to the cohort with FC III symp-
toms (hazard ratio 0.58 [95% CI: 0.39, 0.86]). The statis-
tical analysis for this subgroup interaction suggested that
the reduction in clinical failure events with initial com-
bination therapy was more likely in FC II participants
than FC III participants (p = 0.084, values < 0.1 generally
considered significant for this interaction).
Table 3 shows the number of participants experiencing
each type of first clinical failure event. PAH-related hos-
pitalizations as a first TtCF event were less likely for
participants assigned to initial combination therapy in
FC II and FC III participants. In the FC III combination
therapy group, 10 (6%) patients had initial PAH-related
hospitalizations as their TtCF event as compared to 22
(13%) in the pooled monotherapy group. There were no
hospitalizations for PAH as an initial event in FC II par-
ticipants in the combination therapy group compared to
8 (10%) with hospitalizations for PAH in the monother-
apy group.
Additional PAH-related hospitalizations occurred after
the first clinical failure event. Post-hoc analyses demon-
strated that among FC III participants randomized to
combination therapy, 19 (11%) had a PAH-related
hospitalization over the course of the study compared to
33 (20%) of those in the pooled monotherapy group
(Table 3). In contrast, among the FC II participants ran-
domized to combination therapy, there were no PAH-re-
lated hospitalizations during the study compared to 11
(14%) in those with FC II symptoms assigned to mono-
therapy. At baseline, those 11 participants with FC II
symptoms had modestly higher NT-pro BNP levels and
lower 6MWD, but the distribution of disease severity ap-
peared similar to the entire FC II group (see
Additional file 1).
Secondary endpoints
Participants with FC III symptoms assigned to combin-
ation therapy enjoyed a larger treatment effect in
6MWD at Week 24 as compared to pooled monother-
apy (Fig. 5a, 52 m vs. 22 m median increase; p < 0.001).
Fig. 1 Patient Disposition by WHO Functional Class and Treatment Group
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Total (N = 500)
(n = 253) (n = 247) (n = 126) (n = 121)
Baseline Functional Class FC II FC III FC II FC III FC II FC III FC II FC III FC II FC III
Patients (n) 76 177 79 168 38 88 41 80 155 345
Age, years
Mean 50 56 53 55 52 55 54 55 52 56
SD 16 13 15 15 15 14 15 15 15 14
Female 66% 78% 80% 82% 82% 78% 78% 85% 73% 80%
North Americab 53% 43% 53% 42% 53% 35% 54% 49% 53% 42%
Type of PAH
Idiopathic/ Heritable PAH 53% 53% 58% 59% 58% 60% 59% 58% 55% 56%
PAH associated with connective tissue
diseasea
34% 44% 28% 37% 32% 36% 24% 38% 31% 40%
PAH associated with congenital heart
diseasea
7% 0 4% 1% 3% 0 5% 1% 5% < 1%
Hemodynamic variables (mean ± SD)


















































































































FC Functional class, PAH Pulmonary arterial hypertension, SD Standard deviation, WHO World Health Organization
aPost-hoc summary; bNorth America (vs. Rest of World, mostly Western Europe), cValues have been rounded to two significant digits for ease of comparison
Fig. 2 Baseline Values of 6MWD (a) and NT-proBNP (b) by WHO Functional Class and Treatment Group
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The difference between treatment groups for improve-
ment in walk was not significant for those with baseline
FC II symptoms (40 m vs. 32 m median increase, p =
0.366).
Fifty-three percent (53%) of FC II participants random-
ized to combination therapy demonstrated a satisfactory
clinical response (defined as a ≥ 10% improvement in
6MWD over baseline, FC I or II symptoms at Week 24,
and no event of clinical worsening through week 24),
compared to 43% of the pooled monotherapy group (p =
0.243). Among FC III participants, corresponding re-
sponse rates were 33 and 23%, respectively (p = 0.044).
A post-hoc analysis demonstrated that NT-proBNP
levels dropped from baseline to Week 24 in both FC II
and III participants (Fig. 5b). NT-proBNP fell more
among FC III participants randomized to combination
therapy vs. pooled monotherapy (geometric mean ratio
expressed as difference, − 43% [95% CI: − 54, − 29], p <
0.001). Reductions in NT-proBNP for FC II participants
were comparable between the two treatment groups
(p = 0.380).
Safety
In both functional classes, adverse events were generally
more frequent in the combination therapy vs. monother-
apy groups for the events listed in Table 4. For the com-
mon events of headache, nasal congestion, and
nasopharyngitis, less symptomatic FC II participants re-
ported more of these events than FC III participants
when assigned to combination therapy. Edema was more
often reported for participants randomized to combin-
ation (45%) than monotherapy (28–33%), but this did
not vary between the functional classes. Therapy discon-
tinuations for adverse events were unusual but more
Fig. 3 Kaplan-Meier Curves Showing the Probability of First Adjudicated Primary Endpoint (Clinical Failure) Event by Treatment Group and Functional Class
Fig. 4 Forest Plot of Time to First Clinical Failure Event by WHO Functional Class and Treatment Group (Primary Analysis Set)
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common in those with FC III symptoms; discontinua-
tions did not differ between treatment assignments.
Seven FC II patients (9%) on combination therapy and 8
FC II patients (10%) on monotherapy discontinued treat-
ment due to adverse events compared to 29 FC III pa-
tients (16%) on combination therapy and 34 FC III
patients (20%) on monotherapy.
Discussion
Initial combination therapy with ambrisentan and tada-
lafil reduced the risk of clinical events by 50% as com-
pared to those assigned monotherapy, an effect driven
by a substantial reduction in hospitalizations. Previous
studies have generally found the largest treatment effects
in participants with more advanced symptoms at enroll-
ment, and we anticipated similar results. Instead, for the
primary endpoint of clinical worsening, the benefit fa-
voring initial combination therapy was numerically lar-
ger for participants with FC II symptoms at baseline.
There were no PAH-related hospitalizations in FC II
participants assigned to combination therapy.
This is the first controlled study of initial combination
therapy in PAH, and our hypotheses were driven by
older trials of monotherapy and more recent studies of
sequential combination therapy. Benefits in exercise tol-
erance tended to be greater for participants with more
advanced symptoms in the registration trials for sub-
cutaneous treprostinil [8] and sildenafil [9]. In recent se-
quential combination therapy studies for riociguat [5]
and macitentan [4], exercise tolerance benefits were
similarly muted in FC II participants as compared to
those in FC III. .
In the present study, while the overall hospitalization
and TtCF event rates were lower in the FC II vs. FC III
subgroups, the treatment impact of combination therapy
in the FC II participants was numerically greater as com-
pared to those with FC III symptoms (Fig. 4). Moreover,
over a median treatment exposure of 76 weeks, there
were no PAH-related hospitalizations (nor initiation of
parenteral prostacyclin) in the FC II combination ther-
apy cohort compared to 11 PAH-related hospitalizations
(14%) in the FC II monotherapy cohort (median expos-
ure 69 weeks in pooled monotherapy). Importantly, this
analysis of AMBITION argues that despite having FC II
symptoms, treatment naïve patients are still at risk for
events including costly hospitalization. Many of the FC
II participants had intermediate or high-risk elevations
in NT-pro-BNP, emphasizing the importance of a multi-
faceted risk evaluation as recently recommended [10,
11]. One caution: this is the primary analysis set of the
AMBITION data, excluding those with excess morbid-
ities which suggest left heart disease. The results might
not apply to a group with comorbidities typical of an
older Western population.
Even considering a multi-modal risk-assessment strat-
egy [12, 13], the 11 FC II participants who had PAH-re-
lated hospitalizations on monotherapy did not appear to
be the ‘sickest’ of the FC II participants (see details in
Additional file 1). This observation suggests that predict-
ing hospitalization among FC II patients is difficult and
Table 3 Summary of First Clinical Failure Events and First PAH Hospitalizations by WHO Functional Class and Treatment Group
(Primary Analysis Set)
Combination Therapy Pooled Monotherapy Ambrisentan Monotherapy Tadalafil Monotherapy
(n = 253) (n = 247) (n = 126) (n = 121)
Baseline Functional Class FC II FC III FC II FC III FC II FC III FC II FC III
(n = 76) (n = 177) (n = 79) (n = 168) (n = 38) (n = 88) (n = 41) (n = 80)
First Clinical Failure Events
Number (%) of patients
with event
4 (5) 42 (24) 17 (22) 60 (36) 9 (24) 34 (39) 8 (20) 26 (33)
Death 3 (4) 6 (3) 1 (1) 7 (4) 0 2 (2) 1 (2) 5 (6)
PAH Hospitalization 0 10 (6) 8 (10) 22 (13) 5 (13) 13 (15) 3 (7) 9 (11)
Disease Progression 0 10 (6) 5 (6) 11 (7) 3 (8) 9 (10) 2 (5) 2 (3)
ULTCR 1 (1) 16 (9) 3 (4) 20 (12) 1 (3) 10 (11) 2 (5) 10 (13)













Number (%) of patients with event 0 19 (11) 11 (14) 33 (20) 7 (18) 20 (23) 4 (10) 13 (16)






CI Confidence interval, FC Functional class, N/A Not applicable, PAH Pulmonary arterial hypertension, ULTCR Unsatisfactory long-term clinical response, WHO World
Health Organization
aPost-hoc analysis
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supports the use of initial combination therapy to de-
crease the risk of hospitalization. Using the REVEAL
score to perform a baseline risk stratification, we have
recently reported that initial combination therapy
reduces events even in those at lowest baseline risk; in
fact, similar to the present results, low REVEAL risk par-
ticipants had zero events when assigned to combination
therapy (as compared to 16% of low risk participants
Fig. 5 Change in 6-Minute Walk Distance and NT-proBNP from Baseline at Week 24 by WHO Functional Class and Treatment Group (Primary
Analysis Set). a 6 Minute Walk. Error bars represent 95% confidence intervals. Stratified Wilcoxon Rank Sum analysis: worst rank scores were used
for missing data following death or adjudicated hospitalization; otherwise, last observation carried forward imputation was used. FC = functional
class; WHO=World Health Organization. b NT-pro BNP. Error bars represent 95% confidence intervals. Geometric mean ratio estimates from Mixed
Models Repeated Measures analysis adjusted for randomization stratification factors and baseline value, with no imputation for missing data.
Terms in model: Treatment, Baseline value, Visit, Treatment x Visit, Etiology of PAH (stratification value) and WHO functional class (stratification
value). Stratification values may differ from baseline subgroup values. This is a post-hoc analysis
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assigned to monotherapy) [10]. The present analysis
demonstrates that this is true for all PAH related hospi-
talizations, not just those occurring as the first clinical
failure event.
This analysis stands in contrast to the other two
positive, event-driven studies recently completed. The
majority of the participants in the studies for maci-
tentan [4] and selexipag [6] were on background ther-
apy at study entry. The point estimate of the
treatment effect (risk reduction for clinical events)
was similar in the FC II vs. FC III/IV participants for
both studies, but the statistical significance of the
treatment effect was driven by the FC III/IV partici-
pants. The data in Fig. 4 suggest a numerically
greater treatment effect for FC II participants in AM-
BITION, and the statistical analysis for this subgroup
interaction suggests that indeed FC II participants
had greater benefit. Obviously, GRIPHON and SERA-
PHIN are very different in design from the present
one which focused on treatment-naïve individuals,
and even given the different designs, a subset analysis
of the GRIPHON data did suggest benefit for FC II
participants already on two therapies [14]. One specu-
lative explanation for our data is that treatment naïve
patients with FC II symptoms present a unique op-
portunity to change the disease trajectory if initially
treated with an endothelin receptor antagonist (ambri-
sentan) and a phosphodiesterase inhibitor (tadalafil).
Similar to previously published data (and in contrast
with the primary endpoint data), improvements in walk
distance and reductions in NT-proBNP for combination
therapy vs. monotherapy were muted for patients with
FC II symptoms as compared to those in FC III. This is
entirely compatible with results from SERAPHIN and is
probably easiest understood in terms of the quantitative
aspects of analyzing continuous variables. Baseline
6MWD was lower and baseline NT-proBNP values were
higher for those in FC III as expected, and the number
of participants in FC II was less than half that in FC III.
These factors reduced the likelihood of finding a statisti-
cally significant difference for functional parameters
within FC II participants, although the 6MWD did im-
prove by 40 m in the combination therapy group (for
context, a cohort of FC II participants treated with
bosentan had an 11m improvement [15]). There was an
absolute 10% increase in the number of participants who
achieved a ‘satisfactory clinical response’ for FC II partic-
ipants treated with combination ambrisentan and tadala-
fil (vs. pooled monotherapy), and this was identical to
the absolute 10% increase in FC III participants with
combination therapy. CTD-PAH participants were more
likely to be FC III as opposed to FC II but this difference
was parallel in combination and pooled monotherapy
assigned participants.
Nearly all participants reported some adverse effect,
but for the most frequently reported adverse events, FC
Table 4 Most Frequently (≥10% of Patients) Reported Adverse Events Occurring with Higher Frequency in the Combination Therapy
Group (≥5% Difference Between Combination Group and Either Monotherapy Group) in Either WHO Functional Class II or III by
Treatment Group
Adverse Event, n (%)a Combination Therapy (n = 253) Ambrisentan Monotherapy (n = 126) Tadalafil Monotherapy (n = 121)
FC II (n = 76) FC III (n = 177) FC II (n = 38) FC III (n = 88) FC II (n = 41) FC III (n = 80)
Any event 74 (97) 173 (98) 35 (92) 85 (97) 38 (93) 76 (95)
Headache 39 (51) 68 (38) 8 (21) 33 (38) 14 (34) 28 (35)
Edema peripheral 34 (45) 81 (46) 12 (32) 29 (33) 12 (29) 22 (28)
Nasal congestion 22 (29) 32 (18) 8 (21) 11 (13) 5 (12) 10 (13)
Nasopharyngitis 15 (20) 22 (12) 6 (16) 20 (23) 6 (15) 12 (15)
Cough 13 (17) 27 (15) 5 (13) 9 (10) 7 (17) 14 (18)
Dizziness 13 (17) 37 (21) 6 (16) 18 (20) 4 (10) 10 (13)
Pain in extremity 13 (17) 24 (14) 4 (11) 10 (11) 4 (10) 14 (18)
Flushing 12 (16) 26 (15) 5 (13) 13 (15) 4 (10) 7 (9)
Non-cardiac chest pain 11 (14) 16 (9) 2 (5) 8 (9) 2 (5) 6 (8)
Vomiting 11 (14) 17 (10) 3 (8) 8 (9) 3 (7) 9 (11)
Palpitations 10 (13) 18 (10) 5 (13) 15 (17) 3 (7) 14 (18)
Anemia 9 (12) 28 (16) 1 (3) 7 (8) 5 (12) 9 (11)
Bronchitis 8 (11) 19 (11) 1 (3) 4 (5) 4 (10) 6 (8)
Epistaxis 8 (11) 14 (8) 1 (3) 4 (5) 4 (10) 7 (9)
Dyspepsia 6 (8) 23 (13) 0 5 (6) 6 (15) 8 (10)
FC Functional class, WHO World Health Organization
aIncludes adverse events with onset between the first dose of study drug and last dose + 30 days
White et al. Respiratory Research          (2019) 20:208 Page 8 of 10
II participants assigned to combination therapy reported
more events than those in FC III. This observation, how-
ever, did not translate into a greater rate of drug discon-
tinuation, which was in fact higher among FC III
participants. Presumably, participants who were less
symptomatic from PAH were more likely to report head-
ache and nasopharyngeal congestion but ultimately accli-
mated in the context of clinical and functional benefit.
Edema, while more common in those assigned to combin-
ation therapy, was equally prevalent in the two functional
classes and rarely a cause for drug discontinuation.
Conclusions
In summary, initial combination therapy with ambrisen-
tan and tadalafil reduced clinical failure events, princi-
pally PAH-related hospitalizations, among those with FC
II symptoms at baseline. FC III participants assigned to
combination therapy also had fewer clinical failure
events, including PAH-related hospitalization; however,
in contrast to previously published data, the magnitude
of risk reduction for the primary outcome was numeric-
ally greater in those with FC II symptoms at enrollment.
Because the combination was well tolerated and safe,
this data supports recently amended treatment guide-
lines suggesting initial combination therapy, particularly
for patients with FC II symptoms. Clinicians should find
this data valuable in their treatment of newly diagnosed
patients with PAH even when symptoms are relatively
mild.
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